Cambrex Corporation (CBM) Analysts See $1.11 EPS

January 19, 2018 - By reb123z

 Cambrex Corporation (CBM) Analysts See $1.11 EPS
Investors sentiment increased to 1.58 in 2017 Q3. Its up 0.59, from 0.99 in 2017Q2. It improved, as 18 investors sold Cambrex Corporation shares while 61 reduced holdings. 41 funds opened positions while 84 raised stakes. 31.63 million shares or 2.69% more from 30.80 million shares in 2017Q2 were reported.
The United Kingdom-based Ahl Partners Llp has invested 0.06% in Cambrex Corporation (NYSE:CBM). Amalgamated Bancorporation holds 0.01% of its portfolio in Cambrex Corporation (NYSE:CBM) for 4,470 shares. California Pub Employees Retirement Sys accumulated 77,566 shares or 0.01% of the stock. Third Avenue Management Ltd Liability Corporation accumulated 63,085 shares. Fifth Third National Bank reported 344 shares or 0% of all its holdings. Prudential Financial owns 79,913 shares or 0.01% of their US portfolio. Fmr Ltd Limited Liability Company has 0.01% invested in Cambrex Corporation (NYSE:CBM). Northwestern Mutual Wealth Mngmt has invested 0% in Cambrex Corporation (NYSE:CBM). Cim Mangement Incorporated invested in 11,205 shares or 0.22% of the stock. Howe And Rusling owns 50 shares. The Illinois-based Peak6 L P has invested 0% in Cambrex Corporation (NYSE:CBM). Bank Of Montreal Can accumulated 35,621 shares or 0% of the stock. Arizona State Retirement Sys holds 0.01% or 16,976 shares. Federated Pa has 0% invested in Cambrex Corporation (NYSE:CBM). Gemmer Asset Mgmt Ltd has invested 0% of its portfolio in Cambrex Corporation (NYSE:CBM).

Since August 1, 2017, it had 0 buys, and 3 sales for $1.57 million activity.

Analysts expect Cambrex Corporation (NYSE:CBM) to report $1.11 EPS on February, 2.They anticipate $0.07 EPS change or 5.93 % from last quarter’s $1.18 EPS. CBM’s profit would be $36.38M giving it 12.57 P/E if the $1.11 EPS is correct. After having $0.55 EPS previously, Cambrex Corporation’s analysts see 101.82 % EPS growth. The stock decreased 0.36% or $0.2 during the last trading session, reaching $55.8. About 7,839 shares traded. Cambrex Corporation (NYSE:CBM) has risen 11.15% since January 19, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

Among 6 analysts covering Cambrex Corp (NYSE:CBM), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cambrex Corp had 7 analyst reports since July 21, 2015 according to SRatingsIntel. As per Tuesday, January 16, the company rating was maintained by William Blair. Singular Research maintained the shares of CBM in report on Thursday, February 11 with “Buy” rating. On Tuesday, October 31 the stock rating was maintained by Craig Hallum with “Buy”. Stephens initiated the stock with “Overweight” rating in Tuesday, July 21 report. On Monday, November 7 the stock rating was upgraded by First Analysis to “Overweight”. First Analysis maintained the stock with “Overweight” rating in Tuesday, January 17 report.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.83 billion. The company??s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 18.69 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Another recent and important Cambrex Corporation (NYSE:CBM) news was published by Globenewswire.com which published an article titled: “Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at …” on January 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.